golimumab · Simponi

Monoclonal antibody

Also known as CNTO 148

Approvedregulatory verdict

Evidence outlook

Approved: Psoriatic Arthritis, Ulcerative Colitis (label: Adults with moderately to severely active UC who have had an inadequate response to conventional...), Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Crohn's Disease · Phase 2

Also approved (5)
US
  • Adult patients with active ankylosing spondylitis (AS)
Product first approved 2009Outside this platform's coverageFDA label
UK
  • Moderately to severely active ulcerative colitis in adult patients
Product first approved 2013medicines.org.uk
JP
  • Treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not sufficiently responded to conventional treatments
Product first approved 2011PMDA
EU
  • Rheumatoid arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX. Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function. For information regarding the polyarticular juvenile...
Product first approved 2009EMA
CA
  • SIMPONI® (golimumab injection) Rheumatoid Arthritis (RA) Simponi, in combination with methotrexate (MTX), is indicated for: • Reducing signs and symptoms and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. • Inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who had not previously been treated with MTX. Psoriatic Arthritis (PsA) Simponi is indicated for: • Reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in...
Product first approved 2009Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (28)
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT04108468 · The Leeds Teaching Hospitals NHS Trust
2015-10-27 – 2023-07 · Psoriatic Arthritis
What this study did
NCT01871649 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2013-08 – 2018-11 · Psoriatic Arthritis
What this study did
NCT02065713 · Instituto de Medicina Molecular João Lobo Antunes
2014-08 – 2017-06 · Psoriatic Arthritis
What this study did
NCT02181673 · Janssen Research & Development, LLC
2014-09-08 – 2017-03-22 · Arthritis, Psoriatic
What this study did
NCT00265096 · Centocor, Inc.
2005-12 – 2012-01 · Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT00973479 · Centocor, Inc.
2009-09 – 2013-02 · Arthritis, Rheumatoid
What this study did
NCT01248780 · Centocor, Inc.
2010-09 – 2012-07 · Rheumatoid Arthritis
What this study did
NCT00975130 · Merck Sharp & Dohme LLC
2009-09 – 2012-02 · Arthritis, Rheumatoid
What this study did
NCT00727987 · Janssen Pharmaceutical K.K.
2008-05 – 2011-12 · Rheumatoid Arthritis
What this study did
NCT00771251 · Janssen Pharmaceutical K.K.
2008-05 – 2011-10 · Rheumatoid Arthritis
What this study did
NCT00361335 · Centocor, Inc.
2006-09 – 2009-09 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
Other / comorbidity
NCT03270501 · University Ghent
2017-11-08 – 2023-12-14 · Axial Spondyloarthritis
What this study did
NCT01426815 · University Hospital, Ghent
2012-03-13 – 2019-03-18 · Peripheral Spondylarthritis
What this study did
NCT02186873 · Janssen Research & Development, LLC
2014-09-03 – 2016-10-11 · Ankylosing Spondylitis
What this study did
NCT01453725 · Merck Sharp & Dohme LLC
2012-02-13 – 2015-01-15 · Spondylitis, Ankylosing
What this study did
NCT01230827 · Janssen Research & Development, LLC
2010-12 – 2014-05 · Juvenile Idiopathic Arthritis
What this study did
NCT01248793 · Centocor, Inc.
2010-10 – 2012-03 · Ankylosing Spondylitis
What this study did
NCT00265083 · Centocor, Inc.
2005-12 – 2012-01 · Spondylitis, Ankylosing
What this study did
Phase 2/3 (2)
Ulcerative Colitis
NCT00488774 · Janssen Research & Development, LLC
2007-08 – 2009-05 · Colitis, Ulcerative
What this study did
Phase 2 (16)
Crohn's Disease
NCT05242471 · Janssen Research & Development, LLC
2022-07-22 – 2029-11-05 · Crohn's Disease
What this study did
Psoriatic Arthritis
NCT05071664 · Janssen Research & Development, LLC
2021-10-25 – 2024-08-06 · Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT01715896 · MedImmune LLC
2013-03 – 2015-02 · Rheumatoid Arthritis
What this study did
NCT00207714 · Centocor, Inc.
2003-11 – 2006-02 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05242484 · Janssen Research & Development, LLC
2022-09-19 – 2029-03-27 · Colitis, Ulcerative
What this study did
NCT03182166 · Centre Hospitalier Universitaire de Saint Etienne
2017-11-21 – 2021-12-15 · Ulcerative Colitis
What this study did
NCT03662542 · Janssen Research & Development, LLC
2018-11-20 – 2021-11-15 · Colitis, Ulcerative
What this study did
Other / comorbidity
NCT07683026 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2026-08-08 – 2032-09-01 · Type 1 Diabetes (T1D)
What this study did
NCT04729296 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2021-07-01 – 2027-07-01 · Diabetes Mellitus, Type 1
What this study did
NCT05960578 · University of Washington
2024-05-23 – 2026-04-14 · Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
What this study did
NCT04218565 · Wenjie Zheng
2020-02-15 – 2022-12-15 · Behcet Syndrome, Uveitis
What this study did
NCT02846545 · Janssen Research & Development, LLC
2016-08-26 – 2021-01-05 · Diabetes Mellitus, Type 1
What this study did
NCT00675649 · Centocor, Inc.
started 2008-05 · Asthma
What this study did
NCT00207740 · Centocor, Inc.
2004-08 – 2007-07 · Asthma
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01526174 · House Research Institute
2012-03 – 2014-04 · Autoimmune Inner Ear Disease
What this study did
Phase 1 (7)
Psoriatic Arthritis
NCT04152759 · Bio-Thera Solutions
2019-09-09 – 2020-12-31 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT01362153 · Centocor, Inc.
2007-12-26 – 2009-02-27 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
Other / comorbidity
NCT03632759 · Carla Greenbaum, MD
2018-08-15 – 2021-11-09 · Type 1 Diabetes Mellitus
What this study did
NCT03298542 · Janssen Research & Development, LLC
2017-10-16 – 2021-06-01 · Pre-Symptomatic Type 1 Diabetes
What this study did
NCT01258777 · Centocor, Inc.
2010-10 – 2011-04 · Healthy Volunteers
What this study did
NCT01288157 · Centocor, Inc.
2010-09 – 2011-01 · Healthy Adult Chinese Males
What this study did
Phase 4 (22)
Psoriatic Arthritis
NCT03733925 · Johnson & Johnson Private Limited
2019-01-07 – 2021-11-15 · Spondylitis, Ankylosing, Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT01295151 · Julia Brown
2011-08 – 2015-11 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT04156984 · David Drobne
2021-04-07 – 2024-06-18 · Ulcerative Colitis
What this study did
NCT02425865 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
2016-12 – 2023-01 · ULCERATIVE COLITIS
What this study did
NCT01804166 · Janssen Scientific Affairs, LLC
2013-03-21 – 2020-02-28 · Hepatosplenic T-Cell Lymphoma
What this study did
NCT03669029 · Hospital de Manises
2018-10-01 – 2019-12-31 · Colitis, Ulcerative
What this study did
NCT03124121 · Guy's and St Thomas' NHS Foundation Trust
2017-09-05 – 2019-09-30 · Ulcerative Colitis
What this study did
NCT02910375 · Universitaire Ziekenhuizen KU Leuven
2016-12 – 2018-05 · Ulcerative Colitis
What this study did
NCT02318667 · Merck Sharp & Dohme LLC
2015-02-27 – 2017-09-05 · Colitis, Ulcerative
What this study did
NCT02412085 · Istituto Clinico Humanitas
2015-03 – 2017-01 · Colitis, Ulcerative
What this study did
NCT02092285 · Merck Sharp & Dohme LLC
2014-05-09 – 2016-05-25 · Ulcerative Colitis
What this study did
NCT02186886 · Kliniken im Naturpark Altmuehltal
2014-06 – 2015-12 · Ulcerative Colitis
What this study did
NCT02155335 · Merck Sharp & Dohme LLC
2014-07-01 – 2015-10-05 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT07904780 · Oslo University Hospital
2026-11-11 – 2030-11-11 · Juvenile Idiopathic Arthritis (JIA)
What this study did
NCT05164198 · Hanyang University Seoul Hospital
2022-01-15 – 2024-10-31 · Ankylosing Spondylitis, Axial Spondyloarthritis
What this study did
NCT03253796 · Merck Sharp & Dohme LLC
2017-11-07 – 2021-03-17 · Spondyloarthritis
What this study did
NCT02758782 · Charite University, Berlin, Germany
2016-09 – 2021-01 · Ankylosing Spondylitis
What this study did
NCT02687724 · University College Dublin
2016-06 – 2020-02 · Colitis
What this study did
NCT01668004 · Merck Sharp & Dohme LLC
2012-09-03 – 2015-04-30 · Ankylosing Spondylitis
What this study did
NCT01718951 · Tuen Mun Hospital
2012-08 – 2014-10 · Spondyloarthropathy
What this study did
NCT01212653 · Chinese University of Hong Kong
2010-10 – 2013-05 · Ankylosing Spondylitis(AS)
What this study did
Early phase / not applicable (6)
Psoriatic Arthritis
NCT02841176 · Imperial College Healthcare NHS Trust
2016-07 – 2017-09-19 · Psoriatic Arthritis
What this study did
Ulcerative Colitis
NCT02729233 · University of Arkansas
2017-01 – 2017-01-27 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT04156425 · Shanghai Mental Health Center
2020-07-01 – 2024-12-31 · Major Depressive Disorder
What this study did
NCT04531423 · Shanghai Mental Health Center
2020-10-01 – 2022-09-30 · Major Depressive Disorder
What this study did
NCT01610947 · University Hospital, Montpellier
2012-05-14 – 2018-10-18 · Spondyloarthritis
What this study did
NCT01088698 · Medical University of Graz
2010-03 – 2010-10 · Psoriasis
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Psoriatic Arthritis
NCT05669833 · University of Pennsylvania
2023-07-14 – 2027-01 · Psoriatic Arthritis
What this study did
NCT05046431 · Bio-Thera Solutions
2021-05-06 – 2023-10-06 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT05842213 · Alvotech Swiss AG
2023-03-30 – 2024-09-24 · Rheumatoid Arthritis
What this study did
Phase 2 (1)
Rheumatoid Arthritis
NCT01217814 · Sanofi
2010-11 – 2011-09 · Rheumatoid Arthritis
What this study did
Phase 1 (2)
Psoriatic Arthritis
NCT05332730 · Bio-Thera Solutions
2022-08-01 – 2023-07-10 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT05632211 · Alvotech Swiss AG
2022-12-16 – 2023-10-03 · Healthy Adult Subjects
What this study did
Phase 4 (2)
Rheumatoid Arthritis
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05313620 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2022-04-01 – 2026-06-11 · Ulcerative Colitis, Thromboembolism
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Other / comorbidity
NCT02437162 · Janssen Research & Development, LLC
2015-09-03 – 2017-09-06 · Axial Spondyloarthritis
What this study did
NCT02438787 · Janssen Research & Development, LLC
2015-07-31 – 2017-08-31 · Axial Spondyloarthritis
What this study did
Phase 4 (1)
Ulcerative Colitis
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Crohn's Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Golimumab (Simponi): this drugPhase 2Monoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT02499783: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg)
NCT02065570: Percentage of Participants Who Achieved Clinical Remission at Week 4 (Week 4): Induction: Standard Induction Dose 43.7% vs Induction: Higher Induction Dose 43.5%; p=0.939 (Induction: Standard Induction Dose vs Induction: Higher Induction Dose) missed
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02871635: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol).
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Entocort EC)ApprovedSmall moleculeGlucocorticoid receptorWeak signalFeatured results are safety only in this race
Budesonide (Ortikos)
ApprovedUS marketing discontinued
—Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signal
NCT00552058: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported missed
NCT00297648: Mean Change From Baseline in CDEIS (Crohn's Disease Endoscopic Index of Severity) Score at Week 10 Using Local Non-blinded Assessments (Baseline, Week 10): CDP870 400 mg -6.47 score on a scale (95% CI -7.6 to -5.34)
DexamethasoneApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
QUASAR/GALAXI: superior to ustekinumab on pooled endoscopic endpoints
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00094458: Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine)
NCT00269841: Primary end point achieved by 68% (5 mg/kg) and 56% (10 mg/kg) vs 26% on placebo (P=0.002 and P=0.02).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02096861: CDAI-70 response at Week 6: CT-P13 69.4% (77/111) vs originator infliximab 74.3% (81/109); difference -4.9% (95% CI -16.9 to 7.3), above the -20% non-inferiority margin
Infliximab-Dyyb (Zymfentra)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mirikizumab (Omvoh)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03926130: Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab)
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinPartial signal
NCT00032799: Week 10 clinical response (CDAI decrease >=70): natalizumab 56% vs placebo 49% (P=0.05); remission (CDAI <150): 37% vs 30% (P=0.12) missed
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03104413: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1))
NCT03105128: US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Period 1) 24.6% (95% CI 18.2-31.0) vs Risankizumab 600mg (Period 1) 45.2% (95% CI 39.9-50.5) vs Risankizumab 1200mg (Period 1) 41.6% (95% CI 36.3-46.8); p=<0.001 (Placebo (Period 1) vs Risankizumab 600mg (Period 1)), p=<0.001 (Placebo (Period 1) vs Risankizumab 1200mg (Period 1))
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03345849: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Placebo 29.1% (95% CI 22.4-35.8) vs Upadacitinib 45 mg QD 49.5% (95% CI 44.2-54.8); p=<0.0001 (Placebo vs Upadacitinib 45 mg QD)
NCT03345836: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 (Week 12): Part 1 (Double Blind): Placebo 21.1% (95% CI 14.9-27.2) vs Part 1 (Double Blind): Upadacitinib 45 mg 38.9% (95% CI 33.6-44.2); p=<0.0001 (Part 1 (Double Blind): Placebo vs Part 1 (Double Blind): Upadacitinib 45 mg)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT01369355: Number of Participants With Clinical Remission at Week 44 (Week 44): Placebo Subcutaneously (SC) 47/131 (35.9%) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w) 63/129 (48.8%) vs Ustekinumab 90 mg SC q8w 68/128 (53.1%); p=0.040 (Placebo Subcutaneously (SC) vs Ustekinumab 90 Milligram (mg) SC Every 12 Weeks (q12w)), p=0.005 (Placebo Subcutaneously (SC) vs Ustekinumab 90 mg SC q8w)
NCT01369342: Number of Participants With Clinical Response at Week 6 (Week 6): Placebo 60/209 (28.7%) vs Ustekinumab 130 mg 108/209 (51.7%) vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg) 116/209 (55.5%); p=< 0.001 (Placebo vs Ustekinumab 130 mg), p=< 0.001 (Placebo vs Ustekinumab Approximately (~) 6 Milligram Per Kilogram (mg/kg))
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Vedolizumab (Entyvio)ApprovedMonoclonal antibodyα4β7 integrinPartial signal
NCT02611817: Percentage of Participants Achieving Clinical Remission at Week 52 (Week 52): Maintenance Phase: Induction IV + Placebo 34.3% (95% CI 26.3-43.0) vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC 48.0% (95% CI 42.0-54.1); p=0.008 (Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC)
NCT03234907: Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10 (Week 10): Induction Phase: Placebo 24.3% (95% CI 14.8-36.0) vs Induction Phase: Vedolizumab 300 mg 19.4% (95% CI 13.3-26.9); p==0.347 (Induction Phase: Placebo vs Induction Phase: Vedolizumab 300 mg) missed
AfimkibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
DuvakitugPhase 3Monoclonal antibodyTL1APartial signal
NCT05499130: UC cohort, clinical remission at week 14: 36% (450 mg) / 48% (900 mg) vs 20% placebo, placebo-adjusted 16% (p=.050) / 27% (p=.003). CD cohort, endoscopic response: 26.1% (low dose) / 47.8% (high dose) vs 13.0% placebo. P-values are one-sided at a 0.10 significance level.
JNJ-78934804Phase 3CombinationIL-23 p19, TNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Remestemcel-L (Ryoncil)Phase 3Cell therapyAllogeneic MSC therapyPartial signalNo reviewed efficacy summary in this indication
TH-SC01Phase 3Cell therapyMesenchymal stem cells (MSC)Weak signalNo reviewed efficacy summary in this indication
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TulisokibartPhase 3Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 2/3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
AmiselimodPhase 2Small moleculeS1P receptorPartial signal
NCT02378688: Proportion achieving CDAI-100 response at Week 12: amiselimod 0.4mg 19/39 (48.7%) vs placebo 20/37 (54.1%); odds ratio 0.79, 95% CI [0.31, 1.98], not statistically significant. missed
AVB-114Phase 2Cell therapyImplantable cell/biomaterial constructPartial signal
NCT04847739: Combined remission at 9 months: 45.8% (11/24) with AVB-114 vs 8.3% (2/24) with standard of care; difference 38% (95% CI 11 to 60%) (2025-10-29).
AZD7798Phase 2Monoclonal antibodyCCR9Weak signalFeatured results are safety only in this race
ExoFloPhase 2Cell therapyMSC-derived exosomesWeak signalFeatured results are safety only in this race
MT-201Phase 2Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
MT-501Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ObefazimodPhase 2Small moleculemiR-124not yet gradedNo reviewed efficacy summary in this indication
OmilancorPhase 2Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
ZotemtegrastPhase 2Small moleculeα4β7 integrinnot yet gradedNo reviewed efficacy summary in this indication
EcoActivePhase 1/2Microbiome therapeuticBacteriophage (anti-AIEC)not yet gradedNo reviewed efficacy summary in this indication
Furestem-CDPhase 1/2Cell therapyAllogeneic MSC therapyWeak signalNo reviewed efficacy summary in this indication
ICG318Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ALLO-ASCPhase 1Cell therapyAdipose-derived MSC therapyWeak signalNo reviewed efficacy summary in this indication
BDHK-2009Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Hemay007Phase 1Small moleculeTNF-alphaWeak signalNo reviewed efficacy summary in this indication
HRS-7085Phase 1Small moleculeNCBP1/NCBP2 (nuclear cap-binding complex)Weak signalNo reviewed efficacy summary in this indication
IPG11406Phase 1Small moleculeEBI2Weak signalFeatured results are safety only in this race
LMT503Phase 1Small moleculeMacrophage polarization / Cellular metabolismnot yet gradedNo reviewed efficacy summary in this indication
OD-07656Phase 1Small moleculeRIPK2Weak signalNo reviewed efficacy summary in this indication
PALI-2108Phase 1Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
R-3750Phase 1Biologic (subtype unspecified)Dendritic cell targetingnot yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 1Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ABBV-7066
—(overall)
UndisclosedIL-23 + TL1Anot yet gradedNo reviewed efficacy summary in this indication
BalinatunfibDiscontinuedSmall moleculeTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Firategrast (SB-683699)DiscontinuedSmall moleculeVLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4)not yet gradedNo reviewed efficacy summary in this indication
GSK2330811DiscontinuedMonoclonal antibodyOncostatin M (OSM)not yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Simponi (golimumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
November 2029 (1)
Phase 4Juvenile Idiopathic Arthritis (JIA)Not yet recruiting
Est. primary completion 2029-11-11 · NCT07904780 · CT.gov ↗
What to watch
2032 (1)
September 2032 (1)
Phase 2Type 1 Diabetes (T1D)Not yet recruiting
Est. primary completion 2032-09-01 · NCT07683026 · CT.gov ↗
What to watch

See the full readout calendar ↗